Close Menu

NEW YORK – Oncocyte announced Thursday its DetermaRx molecular diagnostic test for non-small cell lung cancer (NSCLC) received coverage from Medicare Administrative Contractor Palmetto GBA.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.